REVISIONS to PARTICIPATING DRUG COMPANY list for MEDICAID DRUG REBATE PROGRAM

For a drug product to be compensable through the Medical Assistance (MA) Program, the company (labeler) that markets the product must participate in the Federal Medicaid Drug Rebate Program.

The below revisions to the list, unless otherwise indicated, are effective April 1, 2022. Terminations and additions apply only to those National Drug Codes (NDCs) beginning with the five-digit labeler code indicated, and not to other NDCs that may be marketed by that company under a different labeler code.

NEW and REINSTATED LABELERS
OYSTER POINT PHARMA, INC. (73521)
QUALLENT PHARMACEUTICALS HEALTH (82009)
KYTHERA BIOPHARMACEUTICALS INC. (61168)
ARGENX US, INC. (73475)
PHARMAESSENTIA CORPORATION (73536)
MODAVAR PHARMACEUTICALS LLC (72241)
CALLIDITAS THERAPEUTICS US, INC. (81749)
CLEARSIDE BIOMEDICAL, INC. (71565)

TERMINATED LABELERS, MANDATORY AND VOLUNTARY
EXCELLIUM PHARMACEUTICAL, INC. (64125)
MARATHON PHARMACEUTICALS, LLC (42998)
BRAEBURN, INC. (58284)
NNODUM PHARMACEUTICALS CORP (63044)
RECKITT BENCKISER, INC. (72854)
MIST PHARMACEUTICALS, LLC (76299)
PORTON BIOPHARMA LIMITED (81561)